Postmarketing surveillance study of asciminib in patients with resistant/intolerant chronic myeloid leukemia in Japan.
Saved in:
| Title: | Postmarketing surveillance study of asciminib in patients with resistant/intolerant chronic myeloid leukemia in Japan. |
|---|---|
| Authors: | Yamaguchi K; Clinical Development Japan CDD 3, Novartis Pharma K.K., Toranomon Hills Mori Tower, 23-1, Toranomon 1-Chome, Minato-ku, Tokyo, 105-6333, Japan. kazuaki.yamaguchi@novartis.com., Aoki M; Clinical Development Japan CDD 3, Novartis Pharma K.K., Toranomon Hills Mori Tower, 23-1, Toranomon 1-Chome, Minato-ku, Tokyo, 105-6333, Japan., Osako R; Clinical Development Japan CDD 3, Novartis Pharma K.K., Toranomon Hills Mori Tower, 23-1, Toranomon 1-Chome, Minato-ku, Tokyo, 105-6333, Japan. |
| Source: | International journal of hematology [Int J Hematol] 2026 Mar 31. Date of Electronic Publication: 2026 Mar 31. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Springer Japan Country of Publication: Japan NLM ID: 9111627 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1865-3774 (Electronic) Linking ISSN: 09255710 NLM ISO Abbreviation: Int J Hematol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
